Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen

Bone Marrow Transplantation

Volumn 17, Issue 5, 1996, Pages 685-689

  Sahebi, F ^a   Copelan, E ^b   Crilley, P ^c   Bolwell, B ^d   Avalos, B ^b   Klein, J ^b   Territo, M ^a   Gajewski, J ^a,e  

^a UCLA MEDICAL CENTER   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c HAHNEMANN UNIVERSITY HOSPITAL   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Busulfan; Cyclophosphamide; Unrelated bone marrow transplantation

Indexed keywords

BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOTOXIN; METHOTREXATE;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CAUSE OF DEATH; CHILD; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; FOLLOW UP; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HUMAN; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MYELODYSPLASIA; PRIORITY JOURNAL; RELAPSE; SURVIVAL;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; BUSULFAN; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA; LEUKEMIA, MYELOID, CHRONIC; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RECURRENCE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 0029976785     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Kernan NA, Bartsch G, Ash RC et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. New Engl J Med 1993; 328: 593-602.
2. Mcglave P, Bartsch G, Anasetti C et al. Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program. Blood 1993; 81: 543-550.
3. Gajewski JL, Ho WG, Feig SA et al. Bone marrow transplantation using unrelated donors for patients with advanced leukemia or bone marrow failure. Transplantation 1990; 50: 244-249.
4. Beatty P, Hansen JA, Thomas ED. Marrow transplantation from HLA-matched unrelated donor for treatment of hematologic malignancies. Transplantation 1991; 51: 443-447.
5. Fay JW, Collins RH, Pinerio L. Allogeneic bone marrow transplantation using unrelated donors. Bone Marrow Transplant 1993; 11 (Suppl 1): 81-82.
6. Gingrich RD, Glader GD, Goeken NE et al. Allogeneic marrow grafting with partially mismatched, unrelated marrow donors. Blood 1988; 71: 1375-1381.
7. Ash RC, Casper JT, Chitambar RC et al. Successful allogeneic transplantation of T cell-depleted bone marrow from closely HLA-matched unrelated donors. New Engl J Med 1990; 322: 485-494.
8. Bearman IS, Applebaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
9. Buckner CD, Clift RA, Applebaum FR et al. Effects of treatment regimens on post-marrow transplant relapse. Semin Hematol 1981; 28: 32-34.
10. Blume KG, Kopecky KJ, Henslee-Downey JP et al. A prospective randomized comparison of TBI-etoposide vs busulfan-cyclophosphamide as preparative regimen for bone marrow transplantation in patients with leukemia who are not in remission: a SWOG study. Blood 1993; 81: 2187-2193.
11. Copelan EA, Biggs JC, Avalos BR et al. Radiation-free preparation for allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia. J Clin Oncol 1992; 10: 237-242.
12. Clift RA, Buckner CD, Thomas ED et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyciophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 84: 2036-2043.
13. Kaplan E, Meier P. Non-parametric estimation for incomplete observation. J Am Stat Assoc 1958; 53: 457-181.
14. Dixon WJ (ed). BMDP Programs in the Biomedical Survivor. University of California: Los Angeles. CA, USA, 1983.
15. McDonald G, Sharma P, Matthews DE et al. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence and predisposing factors. Hepatology 1984; 4: 116-122.
16. Sullivan KM, Weiden PL, Storb R et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989; 73: 1720-1728.
17. Petersdorf EW, Longton G, Annasetti C et al. The significance of HLA DRβ1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood 1995; 86: 1606-1613.
18. Baxter-Lowe LA, Casper JT, Ash RC, HLA-DR and DQ oligotyping improves comparison between bone marrow donors and recipients: HLA-DR disparity associated with severe acute graft-versus-host disease. Blood 1991; 78 (Suppl. 1): 189a.
19. Gajewski J, Cecka M, Tonair R et al. Impact of HLA class II DNA tissue typing on acute graft-versus-host disease and survival in unrelated donor bone marrow transplants. Blood 1994; 84 (Suppl. 1): 393a.
20. Martin PJ. Increased disparity for minor histocompatibility antigens as a potential cause of increased GVHD risk in bone marrow transplantation from unrelated donors compared with related donors. Bone Marrow Transplant 1991; 8: 217-223.
21. Anasetti C, Amos D, Beatty PG et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. New Engl J Med 1989; 320: 197-204.
22. Beatty PG, Clift RA, Mickelson EM et al. Marrow transplantation from related donors other than HLA-identical siblings. New Engl J Med 1985; 313: 765-771.
23. Horowitz MM, Klein JP, Zhang MJ et al. Who is the best bone marrow donor? A comparison of HLA-mismatched related and unrelated donor transplants for leukemia. Blood 1994; 84 (Suppl. 1): 393a.
24. Weiden PL, Sullivan KM, Flournoy N et al. Antileukemic effect of GVHD in human recipients of allogeneic marrow grafts. New Engl J Med 1979; 300: 1068-1073.